Gastrointestinal Medicines · LP-078
Famotidine Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-078Gastrointestinal Medicines
- Generic identity
- FamotidineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-078
- Generic identity
- Famotidine
- Presentation
- Tablet
- Catalogue strength
- 20 mg; 40 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Famotidine.
- Dosage form: Tablet.
- Catalogue strength / concentration: 20 mg; 40 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Strength-specific finished-product composition, score/alteration instructions and dissolution specification.
- Controlled SKU mapping for 20 mg and 40 mg presentations.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 20 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer score, splitting, dose conversion or interchangeability between strengths. |
| B | 40 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer score, splitting, dose conversion or interchangeability between strengths. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Famotidine is a histamine H2-receptor antagonist that reduces stomach acid secretion. It is used in selected acid-related conditions, with the authorized indication and duration differing by product and country. Symptom relief does not establish the cause of recurrent upper-abdominal discomfort. This ingredient education does not constitute Luang Pharma approved labeling, a diagnostic assessment or advice to continue acid suppression indefinitely.
Clinical context and therapeutic role
A clinician or pharmacist should distinguish uncomplicated heartburn from symptoms that require investigation. Difficulty swallowing, gastrointestinal bleeding, unexplained weight loss or persistent vomiting are warning features. Kidney function is relevant to selection and may affect exposure. Other medicines can depend on stomach acidity for absorption, so medication review is useful. Continued or recurrent symptoms need reassessment; a tablet-strength listing cannot determine whether acid suppression is the right clinical approach.
Selected safety context
Headache, constipation or diarrhoea may occur. Confusion or other central nervous system effects can be more relevant in vulnerable patients, including those with renal impairment. Rare severe allergy or rhythm-related problems require medical assessment. Black stools, vomiting blood, progressive swallowing difficulty or marked deterioration should not be treated simply by increasing an acid-suppressing medicine. The exact local label should guide renal precautions, interactions and any restrictions on unsupervised use.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: FamotidineArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-078.
Professional enquiries
Request product-specific evidence for LP-078.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.